Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Jan. 9 Financial Quick Takes: Closes for two royalty funds; plus Apellis leads follow-on trio, Element, Omniome, Hinova, Emergex, Tscan, Calliditas

HealthCare Royalty, Sagard close royalty funds
HealthCare Royalty Partners closed its HealthCare Royalty Partners IV fund at $1.8 billion. The firm also promoted four team members to managing director: Carlos Almodóvar, head of IR; Shin Kang, head of research; Andrew Reardon, chief legal officer; and Spencer Schneider, chief compliance officer and IP counsel.

Sagard Holdings

Read the full 542 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE